内分泌治疗和中药协同治疗对前列腺癌患者前列腺特异性抗原动态变化与疾病预后的相关分析

Endocrine Therapy and TCM on PSA of Prostate Cancer Patients and Its Prognosis

目的:观察前列腺癌患者采用内分泌治疗后前列腺特异性抗原(PSA)的变化水平,并且评价相关的临床预后指标同时。方法:前瞻性收集2010年6月—2015年6月华北理工大学附属医院入院收治的前列腺组织病理确诊前列腺癌患者58例,随机分为内分泌治疗组与对照组,内分泌治疗组患者在对照组常规治疗基础上结合比卡鲁胺、中药予以治疗,对照组为常规方案。比较观察两组患者前列腺特异性抗原(PSA)的变化水平和卡氏(KPS)评分,并通过SAS自评量表评价两组治疗效果。结果:两组治疗方法均可有效改善前列腺癌患者PSA水平。内分泌治疗组79.3%患者PSA水平恢复正常,高于对照组69.0%,但两组间无明显统计学差异(χ2=2.599,P=0.107)。内分泌治疗组KPI评分>70分患者为72.4%,高于对照组62.1%,但两组间无明显统计学差异(χ2=2.261,P=0.133)。内分泌治疗组SAS自评量表评分改善患者多于对照组,但两组间无明显统计学差异(P>0.05)。结论:前列腺癌内分泌治疗能有效降低患者PSA水平、改善患者生活质量,与常规治疗具有等同疗效。

Objective ： To observe the changes of PSA after treatment in patients with prostate cancer by endocrine therapy and TCM and evaluate the prognosis of some clinical indicators. Methods： In our hospital from June 2010 to June 2015,58 prostate cancer patientswere randomly divided into treatment group and control group. The treatment group were treated with endocrine bicalutamide and traditional Chinese medicine treatment. The treatment group used the convention- al scheme. Compare the two groups＇ PSA changes and KPS scorefor the evaluation of the effect of treatment. Use SAS self rating scale for statistical analysis. Results ： The two groups can effectively improve the level of PSA. PSA level of 79. 3 % patients of the treatment group returned to be normal and 69.0% of control group＇ s patients＇ SA level returned to be normal. The KPI score more than 70 of treatment group 72.4% and ofn the control group62%. The results were not statistically significant （P 〉 0. 05）. SAS self rating scale of treatment group was greatly improvedcompared with the con- trol group＇ s. As a result, it had no statistical significance （P 〉 0. 05 ）. Conclusion： The treatment of prostate cancer pa- tients with endocrine therapy has a significant effect on the improvement of PSA and survival quality.